Evidence map›Paper›PMID 25813361›Full record

ReviewExpert opinion on drug delivery2015

Polymeric nanoparticle drug delivery technologies for oral delivery applications.

Eric M Pridgen, Frank Alexis, Omid C Farokhzad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on drug delivery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed.

  1. Review
  2. Intestinal uptake regulates T cell responses to dietary antigens.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  14. State of the art in pediatric nanomedicines.Drug delivery and translational research · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eric M PridgenStanford University, School of Medicine , Stanford, CA 94305 , USA epridgen@stanford.edu.
Frank Alexis
Omid C Farokhzad

Funding

The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of InsulinR01EB015419 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI FAROKHZAD, OMID C, KARNIK, ROHIT N · 2012 to 2015
$2.8M
NCI NIH HHS U54 CA151884NCI NIH HHS U54-CA151884NIBIB NIH HHS R01 EB015419NIBIB NIH HHS R01 EB015419-01
6 · The paper itself

Abstract

introductionMany therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles (NPs) are one technology being developed to enable clinically feasible oral delivery. AREAS COVERED: This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal (GI) barriers using polymeric NPs will be considered, including mucoadhesive biomaterials and targeting of NPs to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations. EXPERT OPINION: There have been many approaches used to overcome the transport barriers presented by the GI tract, but most have been limited by low bioavailability. Recent strategies targeting NPs to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and NPs across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric NP technologies and enable the translation of these technologies to clinical practice.

Indexed as

Drug Delivery SystemsNanoparticlesAdministration, OralAnimalsBiological AvailabilityGastrointestinal TractHumansInsulinIntestinal MucosaPolymersInsulinPolymerschemotherapyinflammatory bowel diseaseinsulinM cellsmucoadhesivesmucosal vaccinationsoral deliverypolymeric nanoparticlestranscytosis

Identifiers

PMID25813361
PMCPMC4835173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.